Target Validation Information
Target ID T79068
Target Name Enoyl-[acyl-carrier-protein] reductase [NADH]
Target Type
Successful
Drug Potency against Target Isoniazid Drug Info IC50 = 0.01~C0.2 g/ml [536068]
(4-benzylpiperidin-1-yl)(p-tolyl)methanone Drug Info IC50 = 5160 nM [528999]
(4-benzylpiperidin-1-yl)(2-fluorophenyl)methanone Drug Info IC50 = 14110 nM [528999]
(4-benzylpiperidin-1-yl)(m-tolyl)methanone Drug Info IC50 = 7390 nM [528999]
N-(2-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide Drug Info Ki = 1 nM [529452]
2-(4-hexyl-2-methoxyphenoxy)pyrimidine Drug Info Ki = 1 nM [529452]
5-hexyl-2-(pyrazin-2-yloxy)phenol Drug Info Ki = 1 nM [529452]
5-hexyl-2-(4-nitrophenoxy)phenol Drug Info Ki = 1 nM [529452]
5-hexyl-2-(pyrimidin-2-yloxy)phenol Drug Info Ki = 1 nM [529452]
5-hexyl-2-(pyridin-3-yloxy)phenol Drug Info Ki = 1 nM [529452]
N-(3-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide Drug Info Ki = 1 nM [529452]
5-hexyl-2-(pyridin-2-yloxy)phenol Drug Info Ki = 1 nM [529452]
5-hexyl-2-phenoxyphenol Drug Info Ki = 1 nM [529452]
5-hexyl-2-(2-nitrophenoxy)phenol Drug Info Ki = 1 nM [529452]
2-(3-aminophenoxy)-5-hexylphenol Drug Info Ki = 1 nM [529452]
N-(4-(diethylamino)phenyl)-2-nitrobenzamide Drug Info IC50 = 4370 nM [530118]
4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide Drug Info IC50 = 19950 nM [530118]
2-bromo-4-methylphenyl 2-nitrobenzoate Drug Info IC50 = 9550 nM [530118]
2-nitro-N-(2,4,5-trichlorophenyl)benzamide Drug Info IC50 = 12020 nM [530118]
N-(3,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide Drug Info IC50 = 7080 nM [530118]
(4-benzylpiperidin-1-yl)(3-chlorophenyl)methanone Drug Info IC50 = 7740 nM [528999]
(4-phenylpiperazin-1-yl)(p-tolyl)methanone Drug Info IC50 = 16640 nM [528999]
N-(2,4-dichlorophenyl)-4-methyl-3-nitrobenzamide Drug Info IC50 = 8710 nM [530118]
2-(4,6-dimethoxypyrimidin-2-yloxy)-5-hexylphenol Drug Info Ki = 1 nM [529452]
2-(2-aminophenoxy)-5-hexylphenol Drug Info Ki = 1 nM [529452]
N-(4-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide Drug Info Ki = 1 nM [529452]
2-(4-aminophenoxy)-5-hexylphenol Drug Info Ki = 1 nM [529452]
N-(3,5-dimethoxyphenyl)-4-methyl-2-nitrobenzamide Drug Info IC50 = 1350 nM [530118]
N-(2,4-dichlorophenyl)-2-nitrobenzamide Drug Info IC50 = 19950 nM [530118]
Pyrazinamide Drug Info IC50 = 20~100 g/ml [536068]
5-octyl-2-phenoxyphenol Drug Info Ki = 1 nM [529404]
5-hexyl-2-(pyridin-4-yloxy)phenol Drug Info Ki = 1 nM [529452]
5-hexyl-2-(3-nitrophenoxy)phenol Drug Info Ki = 1 nM [529452]
2-Hexadecynoic acid Drug Info Ki = 2100 nM [531170]
N-(3,5-dichlorophenyl)-2-nitrobenzamide Drug Info IC50 = 6170 nM [530118]
N-(2,4-dimethylphenyl)-2-nitrobenzamide Drug Info IC50 = 10470 nM [530118]
N-(2,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide Drug Info IC50 = 13800 nM [530118]
References
Ref 536068The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64.
Ref 528999Bioorg Med Chem. 2007 Nov 1;15(21):6649-58. Epub 2007 Aug 15.Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
Ref 528999Bioorg Med Chem. 2007 Nov 1;15(21):6649-58. Epub 2007 Aug 15.Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
Ref 528999Bioorg Med Chem. 2007 Nov 1;15(21):6649-58. Epub 2007 Aug 15.Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 530118Eur J Med Chem. 2009 Sep;44(9):3718-30. Epub 2009 Apr 8.Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.
Ref 530118Eur J Med Chem. 2009 Sep;44(9):3718-30. Epub 2009 Apr 8.Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.
Ref 530118Eur J Med Chem. 2009 Sep;44(9):3718-30. Epub 2009 Apr 8.Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.
Ref 530118Eur J Med Chem. 2009 Sep;44(9):3718-30. Epub 2009 Apr 8.Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.
Ref 530118Eur J Med Chem. 2009 Sep;44(9):3718-30. Epub 2009 Apr 8.Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.
Ref 528999Bioorg Med Chem. 2007 Nov 1;15(21):6649-58. Epub 2007 Aug 15.Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
Ref 528999Bioorg Med Chem. 2007 Nov 1;15(21):6649-58. Epub 2007 Aug 15.Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
Ref 530118Eur J Med Chem. 2009 Sep;44(9):3718-30. Epub 2009 Apr 8.Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 530118Eur J Med Chem. 2009 Sep;44(9):3718-30. Epub 2009 Apr 8.Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.
Ref 530118Eur J Med Chem. 2009 Sep;44(9):3718-30. Epub 2009 Apr 8.Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.
Ref 536068The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64.
Ref 529404J Med Chem. 2008 May 8;51(9):2606-12. Epub 2008 Apr 5.Natural products, small molecules, and genetics in tuberculosis drug development.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 529452Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. Epub 2008 Apr 18.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Ref 531170Bioorg Med Chem. 2010 Nov 1;18(21):7475-85. Epub 2010 Sep 18.2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.
Ref 530118Eur J Med Chem. 2009 Sep;44(9):3718-30. Epub 2009 Apr 8.Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.
Ref 530118Eur J Med Chem. 2009 Sep;44(9):3718-30. Epub 2009 Apr 8.Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.
Ref 530118Eur J Med Chem. 2009 Sep;44(9):3718-30. Epub 2009 Apr 8.Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.